EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

NLGN4X TCR transgenic T cells to treat gliomas

Christoper Krämer, Michael Kilian, Yu-Chan Chih, Alexandros Kourtesakis, Dirk C Hoffmann, Tamara Boschert, Philipp Koopmann, Khwab Sanghvi, Alice De Roia, Stefanie Jung, Kristine Jähne, Bryan Day und 8 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noad172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Christoper Krämer und 19 weiteren Autor:innen. Beteiligte Einrichtung: German Cancer Consortium (DKTK) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Hei…. Hauptthemen laut MEDLINE: Glioblastoma, Cancer Vaccines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIA NIH HHS, Swiss Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuroligin 4 X-linked (NLGN4X) harbors a human leukocyte antigen (HLA)-A*02-restricted tumor-associated antigen, overexpressed in human gliomas, that was found to induce specific cytotoxic T cell responses following multi-peptide vaccination in patients with newly diagnosed glioblastoma.

Methods

T cell receptor (TCR) discovery was performed using droplet-based single-cell TCR sequencing of NLGN4X-tetramer-sorted T cells postvaccination. The identified TCR was delivered to Jurkat T cells and primary human T cells (NLGN4X-TCR-T). Functional profiling of NLGN4X-TCR-T was performed by flow cytometry and cytotoxicity assays. Therapeutic efficacy of intracerebroventricular NLGN4X-TCR-T was assessed in NOD scid gamma (NSG) major histocompatibility complex (MHC) I/II knockout (KO) (NSG MHC I/II KO) mice bearing NLGN4X-expressing experimental gliomas.

Results

An HLA-A*02-restricted vaccine-induced T cell receptor specifically binding NLGN4X131–139 was applied for preclinical therapeutic use. Reactivity, cytotoxicity, and polyfunctionality of this NLGN4X-specific TCR are demonstrated in various cellular models. Intracerebroventricular administration of NLGN4X-TCR-T prolongs survival and leads to an objective response rate of 44.4% in experimental glioma-bearing NSG MHC I/II KO mice compared to 0.0% in control groups.

Conclusion

NLGN4X-TCR-T demonstrate efficacy in a preclinical glioblastoma model. On a global scale, we provide the first evidence for the therapeutic retrieval of vaccine-induced human TCRs for the off-the-shelf treatment of glioblastoma patients.Keywords cell therapy | glioblastoma | T cell receptor | tumor antigen

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaCancer VaccinesMiceAnimalsHumansVaccines, SubunitReceptors, Antigen, T-CellT-LymphocytesAntigens, NeoplasmCell Adhesion Molecules, Neuronal

Stichwörter der Autor:innen

Keywords cell therapyT cell receptorglioblastomatumor antigen

Substanzen

Cancer VaccinesVaccines, SubunitReceptors, Antigen, T-CellAntigens, NeoplasmNLGN4X protein, humanCell Adhesion Molecules, Neuronal

Autor:innen und Institutionen

  • German Cancer Consortium (DKTK) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Faculty of Bioscience, Heidelberg University, Heidelberg, Germany.
  • Neurology Clinic, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany.
  • DKTK CCU Neurooncology, DKFZ, Heidelberg, Germany.
  • Helmholtz Institute of Translational Oncology (HI-TRON), Mainz, Germany.

Förderung

  • NCI NIH HHS
  • NIA NIH HHS
  • Swiss Cancer Foundation
  • University Heidelberg Foundation
  • German Research Foundation
  • Helmholtz Institute for Translational Oncology
  • Rolf Schwiete Foundation

Zitieren

APA

Krämer, C., Kilian, M., Chih, Y. C., Kourtesakis, A., Hoffmann, D. C., Boschert, T., Koopmann, P., Sanghvi, K., De Roia, A., Jung, S., Jähne, K., Day, B., Shultz, L. D., Ratliff, M., Harbottle, R., Green, E. W., Will, R., Wick, W., Platten, M., & Bunse, L. (2024). NLGN4X TCR transgenic T cells to treat gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad172

Vancouver

Krämer C, Kilian M, Chih YC, Kourtesakis A, Hoffmann DC, Boschert T, et al. NLGN4X TCR transgenic T cells to treat gliomas. Neuro-Oncology. 2024. doi:10.1093/neuonc/noad172

BibTeX
@article{Krmer2024,
  author = {Krämer, Christoper and Kilian, Michael and Chih, Yu-Chan and Kourtesakis, Alexandros and Hoffmann, Dirk C and Boschert, Tamara and Koopmann, Philipp and Sanghvi, Khwab and De Roia, Alice and Jung, Stefanie and Jähne, Kristine and Day, Bryan and Shultz, Lenny D and Ratliff, Miriam and Harbottle, Richard and Green, Edward W and Will, Rainer and Wick, Wolfgang and Platten, Michael and Bunse, Lukas},
  title = {NLGN4X TCR transgenic T cells to treat gliomas},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noad172}
}
Kostenlos starten →